All travel for study-related assessments will be provided for eligible study participants and their caregiver (if applicable).
ABOUT THE VISTA CLINICAL TRIAL
The VISTA clinical trial is studying an investigational (not yet FDA-approved) gene therapy called AGTC-501 for patients with X-linked retinitis pigmentosa (XLRP).
Gene therapy is the process of injecting a healthy gene to replace a damaged or mutated one.
The investigational gene therapy (AGTC-501) is designed to replace the mutated RPGR gene that causes XLRP.
The purpose of the VISTA phase 2/3 clinical trial is to evaluate the safety and effectiveness of AGTC-501 and to determine whether it may help a person with XLRP see better or maintain their current vision.
You or Your Child May Be Eligible for the VISTA Clinical Trial If:
Diagnosed with XLRP and have RPGR gene mutation (confirmed by genetic testing)
Best Corrected Visual Acuity in at least one eye is between 20/32 and 20/200
Between 13 and 50 years of age
Young boy standing next to his family seated on grass pointing to birds in a sunset filled sky.
Clinical research studies help scientists and doctors explore whether a medical therapy is safe and effective in humans. The data gathered from clinical research helps the development of medical therapies, which may improve how patients receive medical care and the way they are treated for their conditions.
There is no guarantee that this investigational gene therapy will improve your or your child’s XLRP symptoms, but what researchers learn may lead to better medications and treatments for patients with XLRP in the future.